Therapeutic options for HER-2 positive breast cancer: Perspectives and future directions

Recondo, Gonzálo

doi:10.5306/wjco.v5.i3.440

Cited by 11 publications

(3 citation statements)

References 96 publications

(96 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Following the identification of the most effective and best tolerated FGFR inhibitor in patients with metastatic disease, we propose that administration of an FGFR inhibitor in the adjuvant setting following initial surgery might show a significant benefit with respect to ECS, reminiscent of trastuzumab in breast cancer [40]. Treating patients with FGFR2 mutation positive EC with anti-FGFR agents at this earlier stage is expected to be more effective due to the reduced burden of tumor cells in the patient and less tumor heterogeneity, resulting in a decrease in the emergence of acquired resistance.…”

Section: Discussionmentioning

confidence: 99%

FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study

Jeske

Ali

Byron

et al. 2017

Gynecologic Oncology

View full text Add to dashboard Cite

Purpose Activating FGFR2 mutations have been identified in ~10% of endometrioid endometrial cancers (ECs). We have previously reported that mutations in FGFR2 are associated with shorter disease free survival (DFS) in stage I/II EC patients. Here we sought to validate the prognostic importance of FGFR2 mutations in a large, multi-institutional patient cohort. Methods Tumors were collected as part of the GOG 210 clinical trial “Molecular Staging of Endometrial Cancer” where samples underwent rigorous pathological review and had more than three years of detailed clinical follow-up. DNA was extracted and four exons encompassing the FGFR2 mutation hotspots were amplified and sequenced. Results Mutations were identified in 144 of the 973 endometrioid ECs, of which 125 were classified as known activating mutations and were included in the statistical analyses. Consistent with FGFR2 having an association with more aggressive disease, FGFR2 mutations were more common in patients initially diagnosed with stage III/IV EC (29/170;17%) versus stage I/II EC (96/803; 12%; p = 0.07, Chi-square test). Additionally, incidence of progression (progressed, recurred or died from disease) was significantly more prevalent (32/125, 26%) among patients with FGFR2 mutation versus wild type (120/848, 14%; p < 0.001, Chi-square test). Using Cox regression analysis adjusting for known prognostic factors, patients with FGFR2 mutation had significantly (p < 0.025) shorter progression-free survival (PFS; HR 1.903; 95% CI 1.177–3.076) and endometrial cancer specific survival (ECS; HR 2.013; 95% CI 1.096–3.696). Conclusion In summary, our findings suggest that clinical trials testing the efficacy of FGFR inhibitors in the adjuvant setting to prevent recurrence and death are warranted.

show abstract

Section: Discussionmentioning

confidence: 99%

FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study

Jeske

Ali

Byron

et al. 2017

Gynecologic Oncology

View full text Add to dashboard Cite

show abstract

“…For example, Her2 and CD30 are both cancer targets against which naked antibodies had been evaluated in a clinical setting before the development of the ADCs ado-trastuzumab emtansine and brentuximab vedotin, respectively. 29 , 30 , 31 More recent research has focused on identifying targets whose biological role in cancer may be unknown, but whose expression profile is mostly restricted to malignant tissue.…”

Section: Discussionmentioning

confidence: 99%

A novel antibody–drug conjugate targeting SAIL for the treatment of hematologic malignancies

Kim

Theunissen

Balibalos

et al. 2015

Blood Cancer Journal

View full text Add to dashboard Cite

Although several new therapeutic approaches have improved outcomes in the treatment of hematologic malignancies, unmet need persists in acute myeloid leukemia (AML), multiple myeloma (MM) and non-Hodgkin's lymphoma. Here we describe the proteomic identification of a novel cancer target, SAIL (Surface Antigen In Leukemia), whose expression is observed in AML, MM, chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). While SAIL is widely expressed in CLL, AML, MM, DLBCL and FL patient samples, expression in cancer cell lines is mostly limited to cells of AML origin. We evaluated the antitumor activity of anti-SAIL monoclonal antibodies, 7-1C and 67-7A, conjugated to monomethyl auristatin F. Following internalization, anti-SAIL antibody–drug conjugates (ADCs) exhibited subnanomolar IC50 values against AML cell lines in vitro. In pharmacology studies employing AML cell line xenografts, anti-SAIL ADCs resulted in significant tumor growth inhibition. The restricted expression profile of this target in normal tissues, the high prevalence in different types of hematologic cancers and the observed preclinical activity support the clinical development of SAIL-targeted ADCs.

show abstract

“…Treatment of HER2-positive breast cancer with chemotherapeutic agents alone elicited a poor response [ 11 , 12 , 13 , 14 , 15 ]. The discovery of tumor-associated antigens (TAA) has facilitated the emergence of immunotherapy.…”

Section: Introductionmentioning

confidence: 99%

Cancer Vaccines, Treatment of the Future: With Emphasis on HER2-Positive Breast Cancer

Pallerla

Abdul²,

Comeau

et al. 2021

IJMS

View full text Add to dashboard Cite

Breast cancer is one of the leading causes of death in women. With improvements in early-stage diagnosis and targeted therapies, there has been an improvement in the overall survival rate in breast cancer over the past decade. Despite the development of targeted therapies, tyrosine kinase inhibitors, as well as monoclonal antibodies and their toxin conjugates, all metastatic tumors develop resistance, and nearly one-third of HER2+ breast cancer patients develop resistance to all these therapies. Although antibody therapy has shown promising results in breast cancer patients, passive immunotherapy approaches have limitations and need continuous administration over a long period. Vaccine therapy introduces antigens that act on cancer cells causing prolonged activation of the immune system. In particular, cancer relapse could be avoided due to the presence of a longer period of immunological memory with an effective vaccine that can protect against various tumor antigens. Cancer vaccines are broadly classified as preventive and therapeutic. Preventive vaccines are used to ward off any future infections and therapeutic vaccines are used to treat a person with active disease. In this article, we provided details about the tumor environment, different types of vaccines, their advantages and disadvantages, and the current status of various vaccine candidates with a focus on vaccines for breast cancer. Current data indicate that therapeutic vaccines themselves have limitations in terms of efficacy and are used in combination with other chemotherapeutic or targeting agents. The majority of breast cancer vaccines are undergoing clinical trials and the next decade will see the fruitfulness of breast cancer vaccine therapy.

show abstract

Therapeutic options for HER-2 positive breast cancer: Perspectives and future directions

Cited by 11 publications

References 96 publications

FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study

FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study

A novel antibody–drug conjugate targeting SAIL for the treatment of hematologic malignancies

Cancer Vaccines, Treatment of the Future: With Emphasis on HER2-Positive Breast Cancer

Contact Info

Product

Resources

About